Celltrion is a global biopharmaceutical company that develops and commercializes antibody biosimilars and novel biologic drugs for the treatment of autoimmune diseases and oncology. The company's portfolio includes Remsima, Truxima, Herzuma, Yuflyma, Vezelma, Omlyclo, Eydenzelt, Steqeyma, Aptozma, and Stovoclo/Oscenbelt, alongside the novel drug Zymfentra. Celltrion is expanding its pipeline into antibody-drug conjugates (ADCs) and bispecific antibodies, with candidates such as CT-P70, CT-P71, CT-P72, and CT-P73 in clinical trials. The company maintains integrated operations spanning research and development, manufacturing, and direct global sales, utilizing production facilities in Korea and the United States. Following the merger with Celltrion Healthcare in 2023, Celltrion manages its own distribution network in Europe, the United States, Asia, and Latin America. The group also includes Celltrion Pharm, which focuses on small-molecule generics and improved new drugs, and operates contract manufacturing services. Celltrion holds strategic partnerships with various biotechnology firms for next-generation modality development.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage celltrion.com
Sector Healthcare IR page celltrion.com/ko-kr/investment/ir
Tags
biosimilars, antibody-drug conjugates, autoimmune diseases, oncology, small-molecule drugs, contract manufacturing, direct sales, biologics, Remsima, Truxima, Herzuma, Yuflyma, Vezelma, Omlyclo, Eydenzelt, Steqeyma, Aptozma, Stovoclo, Oscenbelt, Zymfentra, Celltrion Healthcare, Celltrion Pharm, CT-P13, CT-P10, CT-P6, CT-P17, CT-P16, CT-P39, CT-P42, CT-P43, CT-P47, CT-P41, CT-P44, CT-P53, CT-P55, CT-P51, CT-P70, CT-P71, CT-P72, CT-P73, CT-P59, Lecirunumab, Nesina, Actos, Idalbi
Press page celltrion.com/en-us/company/media-center

Metrics

Valuation  
Market cap ₩ 45.407T
Market cap (USD) $ 33.419B
P/E 28.29
PEG 1.17
P/BV 2.54
P/S 9.27
P/OCF 45.59
P/FCF 55.17
Dividend yield —
Turnover / mcap —
Returns  
ROE 5.9%
ROI 6.0%
ROIC 6.1%
Profit margin 24.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 24.2%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score -11.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 4.162T 3.557T 2.176T 2.284T 1.893T 1.849T 1.128T 982.075B 949.08B 670.581B 603.413B 471.046B 226.208B
Net profit 1.03T 422.692B 535.648B 537.836B 579.465B 517.76B 301.03B 245.755B 368.222B 158.958B 154.09B 109.356B 102.455B
Free cash flow 537.827B 766.812B 327.112B -110.305B 847.78B — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 180.828K 194.8K — — — — — — — — — — —
Price performance 12m -0.07 — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 758B 828B 808B 814B 1.25T 1.1T 1.62T 939B 1.22T 1.79T
↳ YoY growth +14.5% +9.2% -2.5% +0.8% +53.8% -12.1% +47.3% -42.1% +29.4% +47.3%
↳ 5y CAGR +24.4% +16.6% +13.6% +7.7% +14.4% +3.1% +8.3% +7.4%
Other receivables (KRW) — — — — — — 32.2B 10.2B 45.2B 51.5B
Cash and deposits (KRW) 268B 419B 411B 546B 684B 1.19T 551B 565B 996B 1.12T
Intangible assets (KRW) 720B 788B 885B 1.01T 1.4T 1.49T 1.62T 13.3T 13.7T 13.8T
Cash flow detail
Operating cash flow (KRW) 230B 486B 365B 474B 351B 911B 864M 537B 902B 646B
Purchases of property, plant and equipment (KRW) — — — — — -63.4B -111B -210B -135B -108B
Purchases of intangible assets (KRW) — — — — — -258B -201B -144B -198B -224B
Dividends paid (cash effect) (KRW) — — — — — -3.78M -102B -51.7B -104B -154B
Share buybacks (cash effect) (KRW) — — — — — -39.1B -281B -917B -436B -907B
Interest paid (cash effect) (KRW) — — — — — -16B -22.7B -41.8B -75.2B -82.8B
Income taxes paid (cash effect) (KRW) -45.2B — — — — -136B -217B -154B -145B -444B
Free cash flow (OCF - PPE - intangibles) (KRW) — — — — — 590B -311B 183B 568B 314B
Income detail
Total comprehensive income (KRW) 147B 380B 240B 295B 529B 615B 566B 544B 925B 779B
Comprehensive income to owners (KRW) 157B 370B 248B 294B 521B 599B 562B 540B 929B 777B
Reported May 12, 2022 May 12, 2022 May 12, 2022 May 12, 2022 May 12, 2022 Mar 18, 2024 Mar 17, 2025 Nov 14, 2024 Mar 17, 2025 Mar 16, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Celltrion (ticker 068270), listed in South Korea.

ETFs Holding Celltrion

ETF Weight in ETF Shares Market value As of
DGRE 0.76% 10,084 $ 1.128M Jun 30, 2026
DFEV 0.42% 59,693 $ 9.4M Nov 12, 2026
DFAE 0.16% 95,270 $ 15.002M Nov 12, 2026
NTSE 0.15% 782 $ 87.472K Jun 30, 2026
DFSE 0.15% 5,627 $ 886.058K Nov 12, 2026
DFEM 0.10% 56,902 $ 8.96M Nov 12, 2026
TIER 0.09% 241 $ 31.058K Jul 31, 2026
AVSE 0.08% 1,021 $ 161.634K Nov 16, 2026
DEXC 0.07% 1,098 $ 172.897K Nov 12, 2026
AVEM 0.04% 67,914 $ 10.751M Nov 16, 2026
AVXC 0.04% 1,152 $ 182.372K Nov 16, 2026
JSTC 0.03% 503 $ 80.762K Nov 17, 2026
DFAX 0.03% 20,688 $ 3.258M Nov 12, 2026
DEHP 0.01% 247 $ 38.894K Nov 12, 2026